Trial Profile
Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 17 Feb 2021 Primary endpoint (Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)) has not been met, as per results published in the Neurology
- 17 Feb 2021 Status changed to discontinued, as per results published in the Neurology
- 17 Feb 2021 Results published in the Neurology